1	Evaluation of the Access Bio CareStart™ rapid SARS-CoV-2 antigen test in asymptomatic
2	individuals tested at a community mass-testing program in Western Massachusetts
3	
4	Authors:
5	Sara Suliman ^{1*#} , Wilfredo R. Matias ^{2*} , Isabel R Fulcher ^{3,4} , Francisco J. Molano ^{5,6} , Shannon
6	Collins ⁵ , Elizabeth Uceta ⁵ , Jack Zhu ⁵ , Ryan M. Paxton ⁷ , Sean F. Gonsalves ⁷ , Maegan V. Harden ⁸ ,
7	Marissa Fisher ⁸ , Jim Meldrim ⁸ , Stacey Gabriel ⁸ , Molly F. Franke ³ , Deborah T. Hung ⁸ , Sandra C.
8	Smole ⁹ , Lawrence C. Madoff ⁹ , Louise C. Ivers ^{3,5}
9	
10	¹ Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard
11	Medical School, Boston, MA, USA
12	² Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
13	³ Department of Global Health and Social Medicine, Harvard Medical School, 641 Huntington
14	Avenue, Boston, MA 02115, USA
15	^₄ Harvard Data Science Initiative, Cambridge, MA, USA
16	⁵ Center for Global Health, Massachusetts General Hospital, Boston, MA, USA
17	⁶ Faculty of Medicine, University of Antioquia, Medellín, Antioquia, Colombia
18	⁷ Board of Health, City of Holyoke, Holyoke, MA, USA
19	⁸ Broad Institute of MIT and Harvard, 415 Main St. Cambridge, MA
20	9Massachusetts Department of Public Health, Jamaica Plain, MA, USA
21	
22	*Contributed equally

25

26	#Corresponding	Author: Sara	Suliman,	MPH, PhD.,	Division o	f Rheumatology,	Inflammation
----	----------------	--------------	----------	------------	------------	-----------------	--------------

- and Immunity, Brigham and Women's Hospital, Boston MA Email: ssuliman1@bwh.harvard.edu
- 28 **Running title:** Performance of CareStart[™] SARS-CoV-2 rapid antigen test

29

30 Word Count: 3,383

31 Key words: COVID-19; Rapid antigen test; SARS-CoV-2; CareStart™; asymptomatic

32 Abstract (200 words)

Background: Point-of-care antigen-detecting rapid diagnostic tests (RDTs) for Severe Acute
 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) represent a scalable tool for SARS-CoV-2
 infections surveillance. Data on their performance in real-world community settings is paramount
 for their implementation.

37 Method: We evaluated the accuracy of CareStart[™] COVID-19 Antigen test (CareStart) in a 38 testing site in Holyoke, Massachusetts. We compared CareStart to a SARS-CoV-2 reverse 39 transcriptase quantitative polymerase chain reaction (RT-qPCR) reference, using anterior nasal 40 swab samples. We calculated the sensitivity, specificity, and expected positive and negative 41 predictive values at different SARS-CoV-2 prevalence estimates.

42 **Results:** We performed 666 tests on 591 unique individuals. 573 (86%) were asymptomatic. 43 There were 52 positive tests by RT-qPCR. The sensitivity of CareStart was 49.0% (95% 44 Confidence Interval (CI): 34.8 - 63.4) and specificity was 99.5% (95% CI: 98.5 - 99.9). Among 45 positive RT-qPCR tests, the median cycle threshold (Ct) was significantly lower in samples that 46 tested positive on CareStart. Using a Ct \leq 30 as a benchmark for positivity increased the sensitivity 47 to 64.9% (95% CI: 47.5 - 79.8).

48 Conclusions: CareStart has a high specificity and moderate sensitivity. The utility of RDTs, such
 49 as CareStart, in mass implementation should prioritize use cases in which a higher specificity is
 50 more important.

52 Introduction

53 The Coronavirus disease 2019 (COVID-19) pandemic caused by the Severe Acute 54 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the most significant infectious disease 55 pandemic in the last century (1, 2). In addition to preventive measures such as social distancing, 56 mask wearing, and vaccination, pillars of pandemic control rely on tools to rapidly identify cases 57 and monitor transmission (3). Molecular testing methods based on reverse transcription 58 quantitative polymerase chain reactions (RT-gPCR) remain the backbone of many testing 59 programs globally (4). However, RT-qPCR-based testing is heavily influenced by supply chain restrictions, need for trained personnel and central laboratories, and relatively long turnaround 60 61 times, particularly in resource-constrained settings (5). Therefore, it is still challenging to scale up 62 RT-gPCR tests for population surveillance and the timely detection of the large proportion of 63 asymptomatic SARS-CoV-2-infected carriers (6). Rapid detection of SARS-CoV-2 infected 64 individuals allows for faster clinical intervention and implementation of public health measures 65 such as isolation and contact-tracing, to prevent forward transmission (7).

66 Rapid antigen-detecting diagnostic tests (RDTs) for COVID-19, many of which can yield 67 actionable results in turnaround times often below 20 minutes, require little laboratory capacity, 68 and can be performed easily by non-laboratory personnel (8). Furthermore, decentralized access 69 to RT-qPCR testing remains sparse in resource-constrained communities (9). The low cost of 70 antigen-detecting RDTs, short turnaround times and ease of use make them excellent candidates 71 to increase their accessibility for large-scale implementation in varied community settings (10).

Since the pandemic's onset, several antigen-detecting RDTs have been developed for the detection of SARS-CoV-2 (11). Many of the antigen-detecting RDTs received Emergency Use Authorization (EUA) approvals by the Food and Drug Administration (FDA) (12). However, evaluations to receive EUA were performed by demonstrating accuracy in symptomatic individuals only (13). This narrow indication for antigen-detecting RDTs raises their limited utility

77 in detecting SARS-CoV-2 infection in asymptomatic carriers. In fact, several independent 78 evaluations demonstrate the decreased sensitivity of antigen-detecting RDTs in asymptomatic 79 RT-gPCR positive individuals compared to those with symptoms (14-17). In the United States, 80 studies thus far have focused on 3 RDTs: Quidel Sofia[™] (8, 18), BD Veritor[™] (13, 19) and Abbott 81 BinaxNOW[™] (15, 16, 20). On March 31st, 2021, the FDA also authorized these tests for home 82 use, raising concerns about misinterpretation of false negative results (21). Therefore, evidence 83 to establish their performance characteristics to guide their implementation in real-world settings 84 is even more urgent now.

In this study, we evaluated the Access Bio CareStart[™] COVID-19 RDT (CareStart), a chromatographic antigen-detecting lateral flow immunoassay that received EUA by the FDA (12, 17). We evaluated CareStart in asymptomatic and mildly symptomatic individuals presenting for routine testing at one of the 'Stop the Spread' free community testing sites in Holyoke, Massachusetts. Public health messaging for testing at these community testing sites targeted asymptomatic individuals. We evaluate the sensitivity, specificity, and positive (PPV) and negative predictive values (NPV) as a function of different prevalence scenarios.

92

93

94 Methods

95 Study Population and Ethical Approval

This was a prospective evaluation using convenience sampling of asymptomatic and mildly symptomatic individuals presenting for routine testing for COVID-19. The study was performed between January 6 and February 26, 2021, at the Holyoke "Stop the Spread" walk-up testing site, a free Massachusetts public testing program, which targets asymptomatic individuals (https://www.transformativehc.com/stopthespread.html). The testing site was open three days a week. Individuals who presented to the site during testing hours were approached by our research

102 staff who explained the nature of the study, risks, benefits, and answered any questions before 103 inviting individuals to participate in the study. Verbal consent was obtained from participants to 104 collect a second anterior nasal swab as well as from guardians of minors below 18 years of age, 105 from whom verbal assent was also obtained. The participants were treated in accordance with 106 Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was 107 approved by the Partners Institutional Review Board (Protocol ID: 2020P003892).

108

109 Study intake and data collection

110 After enrollment in the study, our study staff implemented an intake guestionnaire capturing 111 information on participant demographics, presence or absence of symptoms based on case 112 definitions from the Council for State and Territorial Epidemiologists (22): cough, sore throat, 113 chills, shortness of breath, fever, muscle aches or soreness, nausea, vomiting or diarrhea, 114 decreased sense of smell or taste, loss of appetite, general weakness or fatigue, or headaches. 115 The survey also captured prior COVID-19 testing and potential exposures. Each test was 116 assigned a unique anonymous ID. Data collected was inputted into a secure Research Electronic 117 Data Capture (REDCap) database on encrypted tablets. We used the demographic information 118 and specimen numbers to match the RDTs result with the RT-gPCR data collected at the Broad 119 Institute Clinical Research Sequencing Platform (CRSP) as performed in other studies (15, 23).

120

121 Swab collection procedure

The sample was collected by trained personnel at the city testing site. We used dry anterior nasal (AN) swabs: Puritan 6" Sterile Standard Foam Swab with Polystyrene Handle (Puritan, Guilford). Both anterior nares were swabbed 2 times (5 rotations in each nostril), once for RT-qPCR testing and once for the RDT sample. For practical reasons, the swabs for RT-qPCR and RDT were not always collected in the same order. Both samples were placed inside closed test tubes. The RT-

127 qPCR sample was transported to the Broad Institute at the Massachusetts Institute of Technology. 128 The second anterior nasal swab sample was transported to a nearby testing station and the RDT 129 was performed within an hour of sample collection. The RT-qPCR testing results were interpreted 130 according to the publicly available rubric for the Broad Institute COVID-19 testing program: 131 https://sites.broadinstitute.org/safe-for-school/result-code-information.

132

133 Rapid test procedure

134 The CareStart device came with instructions for use and diagrams. The study staff received a 135 one-hour training prior to the study and practiced the RDT on positive and negative control 136 samples provided in the kit. One operator performed the test at a workstation following the 137 CareStart manufacturer's instructions for use (IFU) (24), took pictures of the tests, read the result 138 as positive or negative, and captured into the electronic data entry forms. Participants with a 139 positive RDT were contacted by phone per request from the Department of Public Health within 140 a twenty-four-hour period, informed of their result, and advised to isolate until they received their 141 RT-qPCR result.

142

143 Reference RT-qPCR standard

The gold standard reference used was the SARS-CoV-2 RT-qPCR laboratory developed test through the Broad Institute CRSP, which is approved by the FDA under EUA. The test provides two cycle threshold (Ct) values, one for the nucleocapsid (N2) gene, and one for an internal positive control RNaseP gene. We compared the sensitivity of CareStart against both the qualitative binary RT-qPCR results and the Ct values of the N2 gene amplification reaction, as previously described (17).

150

151 Statistical analyses

152 We calculated sensitivity, specificity, PPV and NPV of the RDT from 2 x 2 contingency tables 153 using RT-gPCR as the gold standard reference. Tests with undetermined CareStart or RT-gPCR 154 results were excluded from these calculations (n=35; 5.2% of all tests). Sensitivity and specificity 155 were further stratified and compared by presence of symptoms and quantitative Ct values. Median 156 Ct values were compared using the non-parametric unpaired Mann-Whitney Utest, 95% Pearson-157 Clopper confidence intervals (CI) were calculated for sensitivity and specificity estimates. Since 158 RDTs have been reported to have high accuracy among symptomatic individuals (8, 15-17), we 159 also tested whether presence of symptoms would increase the sensitivity of the CareStart RDT. 160 Statistical analyses were conducted using R V3.6.0 (R Core Team 2020).

161

162 **Results**

163 We performed 666 CareStart RDTs from participants who provided verbal consent at the walk-up 164 testing site (Table 1 and Figure 1). The 666 tests performed were comprised of 591 unique 165 participants with 60 participants by chance receiving more than one test, with a total of 75 tests 166 performed in addition to the first test per participant (Supplementary Table 1). Among the 591 167 participants, 47.9% were residents from Holyoke, as identified by their residential zip codes. Just 168 over half the participants (51.9%) identified as female. The mean age was 38.1, and 44.7% of 169 participants identified as Hispanic or LatinX (Table 1A). Among Holyoke participants, 58.7% 170 identified as Hispanic or LatinX (Supplementary Table 2), in line with the reported demographics 171 by the American Community Survey for 2019, which shows that 54% of Holyoke residents 172 identified as LatinX. Participants who tested positive for the CareStart RDT were more likely to 173 report at least one symptom than asymptomatic counterparts (41.9% vs. 12.2%; Chi-square $p < 10^{-10}$ 174 0.0001) (Table 1B).

175 The study staff evaluated the usability of the CareStart devices. All tests showed a positive 176 control band, indicating they were valid. However, plastic in some vial caps was slightly

malformed, making it difficult or impossible to properly cap the vials leading to 4 undetermined
CareStart RDT results out of 666, since the operator could not load the RDT. Of the valid tests,
we noted variable band intensities (Figure 2). The positive test line was sometimes so faint that
a flashlight was necessary to see it.

181 To determine the accuracy of the CareStart RDT, we calculated the concordance between 182 the RDT and RT-gPCR (Table 2). Using all RT-gPCR values below 40 as a positive reference, 183 the sensitivity of the CareStart RDT was 48.1% (95% CI: 34.0%-62.4%), while the specificity was 184 99.0% (95% CI: 97.8%-99.6%) (Table 3). Of the 666 visits, participants reported presence of 185 symptoms 93 (14.0%) times (Table 1B). Cough was the most reported (n=40, 6.0%) symptom, 186 while loss of smell or taste, a more specific COVID-19 symptom, was only reported in 19 visits 187 (2.9%) (Supplementary Table 3). Due to the limited sample size, we only stratified individuals 188 tested by presence (n=93) or absence (n=573) of symptoms to test the CareStart RDT accuracy 189 as a function of symptoms. The sensitivity of CareStart RDT in symptomatic individuals was 190 46.4% (95% CI: 27.5%-66.1%), and the specificity was 100% (95% CI: 95%-100%) 191 (Supplementary Table 4A and 4B). In asymptomatic individuals, the sensitivity of the CareStart 192 RDT was 52.2% (95% CI: 30.6%-73.2%), and the specificity was 99.4% (95% CI: 98.3%-99.9%)

193 (Supplementary Table 4C and 4D).

194 Next, we used Ct values for amplification of the N2 target as a proxy for viral load, where 195 higher Ct values reflected low viral loads, as previously reported (25). The Ct values of samples 196 recorded as negative using the CareStart RDT were significantly higher than positive counterparts 197 (Mann Whitney U p-value < 0.0001, Figure 3). Therefore, we also performed a subset analysis 198 where we only considered samples with a Ct < 30 as positive (Supplementary Table 5A). Using 199 this cut-off, the CareStart RDT sensitivity and specificity were 64.9% (95% CI: 47.5%-79.8%) and 200 99.3% (95% CI: 98.3%-99.8%), respectively (Supplementary Table 5B). Although the CareStart 201 RDT EUA does not indicate a specific Ct threshold for the positivity of the comparator RT-gPCR

(24), these data suggest that applying a more stringent Ct value threshold moderately improvesthe sensitivity of the CareStart RDT.

Positive and negative predictive values of diagnostic tests depend on the prevalence of infections in a population, where a higher prevalence increases the PPV at the expense of the NPV (26). We calculated the PPV and NPV values as a function of prevalence rates up to 10%, where the PPV steeply dropped in prevalence rates lower than 5% (Figure 4). At a sensitivity of 49% and specificity of 99.5% (Table 3), the PPV of CareStart was 49.7% at a SARS-CoV-2 infection prevalence of 1%, and 91.6% at a prevalence of 10%. In contrast, the NPV was 99.5% at a prevalence of 1%, and 94.6% at a prevalence of 10%.

211 Finally, our cohort included individuals who presented to the testing site multiple times, 212 who had at least one positive RT-gPCR test result. Therefore, we performed an exploratory 213 analysis of their longitudinal test results (Supplementary Table 1 and Figure 5). We enrolled 5 214 participants who converted from a negative to positive on RT-qPCR tests, all of which were 215 accurately detected as positive by the RDT. Two participants with both positive RT-gPCR and 216 RDT test results reverted to negative test results on both platforms. However, one participant 217 converted from a positive to negative RDT test result but was detected as positive by the RT-218 gPCR on the second test, which was conducted in less than a week.

219

220 Discussion

Antigen-detecting RDTs could provide a scalable and affordable alternative to molecular tests (27). In this study, we present a prospective evaluation of the CareStart antigen-detecting RDT for SARS-CoV-2 detection in a walk-up community COVID-19 testing site in Holyoke, Western Massachusetts. The SARS-CoV-2 testing gap refers to the disparity between where communities rank with respect to numbers of tests performed per 100,000 individuals, and where they rank with respect to SARS-CoV-2 positivity rates in each state (28). Equitable implementation

of testing should lead to higher numbers of tests performed per capita in communities with higher proportions of COVID-19 cases (29). In the state of Massachusetts, the SARS-CoV-2 testing gap, was higher in communities with a high social vulnerability index, including Holyoke, highlighting the socioeconomic disparities underlying access to COVID-19 testing (28). Thus, scaling up affordable tests such as antigen-detecting RDTs can help fill this testing gap, following evaluation of their accuracy and implementation feasibility.

233 Compared to a RT-qPCR-based test, we found a much lower sensitivity (49.0%) than what 234 was reported in the FDA package insert (87.2%), which was restricted to 39 symptomatic 235 individuals within 5 days of symptom onset (24). However, this sensitivity was consistent with the 236 reported sensitivity of CareStart in asymptomatic individuals recruited in a recent study at 237 Lawrence General Hospital in Massachusetts (84.8%) (17). Compared to the Abbott BinaxNOW 238 RDT, which has been validated in several studies including a recent study in Massachusetts, the 239 sensitivity of the CareStart RDT was lower overall and when using a Ct positivity cutoff of ≤ 30 240 (15). The specificity of both tests was comparable at nearly > 99 %. Consistent with several 241 studies, the sensitivity of antigen detecting RDTs was modest in individuals with no or mild 242 symptoms (8, 14-16, 20). Although viral loads (30) and recovery of viable virus (31) peak in the 243 early days following symptom onset, transmission by asymptomatic individuals remains a main 244 driver of the pandemic (6), especially since absence of symptoms removes the prompt to 245 guarantine. Therefore, implementation of antigen-detecting RDTs needs to weigh the benefits of 246 rapid detection of SARS-CoV-2-infected individuals with the lower sensitivity of these tests in 247 asymptomatic carriers (27). On the other hand, the high specificity of these tests reduces the 248 probability of false positive SARS-CoV-2 test results, that would have otherwise led to restrictions 249 and inconveniences that may interfere with the livelihood of these individuals.

Evaluation of RDTs against a highly sensitive gold standard such as RT-qPCR are important to define performance characteristics. The RT-qPCR cycle threshold (Ct) values had a

252 clear impact on the sensitivity of the CareStart RDT, where concordant results showed lower Ct 253 values. In contrast, discordant results had higher Ct values, a proxy for lower viral load, as 254 reported in other evaluations (15, 17, 32). Consistent with this, the CareStart RDT sensitivity 255 improved with a RT-gPCR positivity Ct cut-off of < 30. These data suggest that the CareStart RDT 256 positivity meant higher viral load, which correlates with infectivity of cells in vitro (33), and likely 257 transmissibility. Individuals vaccinated with the Pfizer/BioNtech BNT162b2 vaccine, with 258 breakthrough SARS-CoV-2 infections have been reported to show higher Ct values post-259 vaccination than unvaccinated counterparts, which correlates with lower viral loads (34). The 260 implication, however, is that vaccinated individuals with breakthrough SARS-CoV-2 infections, will 261 be more difficult to detect by antigen-detecting RDT with similar performance characteristics to 262 CareStart. In a study in skilled nursing facility in Chicago, few and mostly asymptomatic break-263 through infections were identified post-vaccination (35). However, two were hospitalized and one 264 died of COVID-19, suggesting that false negative diagnosis of SARS-CoV-2 infections are likely 265 in postvaccination breakthrough infections (35). Therefore, it is crucial to evaluate the accuracy 266 of RDTs in populations with high vaccination rates. Furthermore, false negative results of antigen-267 detecting RDTs may be caused by SARS-CoV-2 variants, which may be more transmissible (36). 268 In laboratory studies, lower RT-gPCR Ct values were shown to correlate with increased recovery 269 of viable virus (31, 37). However, epidemiological studies to support the higher contagiousness 270 of individuals with lower Ct values are still lacking. Furthermore, our study shows overlapping RT-271 qPCR Ct values that could be either detected as positive or negative by the CareStart RDTs. 272 Furthermore, 4 out of 26 negative RDT tests results corresponding to a positive RT-gPCR test 273 result showed relatively low RT-gPCR Ct values (Ct < 25), indicating that false negative RDT 274 results can occur even at high viral loads. Thus, to understand the public health implications of 275 test results, it is imperative to definitively determine the infectiousness of individuals with a positive 276 RT-gPCR, but negative RDT result, even if those negative calls only occurred occasionally.

277 Although our sample of repeat testers was limited, it suggested that individuals who 278 recently converted from negative to positive RT-gPCR test, i.e. recently acquired SARS-CoV-2 279 infection, were easily detectable by the CareStart RDT. Recently infected individuals have been 280 shown to be more contagious (25). Samples from these recently infected individuals had low Ct 281 values, and were thus more likely to transmit the virus (33). Alternatively, the one participant with 282 a "false negative" RDT result after testing positive twice with the RT-gPCR, showed a relatively 283 high RT-gPCR Ct value of 36.4 on the second discordant result, suggesting lower 284 contagiousness. Repeat testing may be influenced by school or work requirements and may 285 reflect a population with a higher susceptibility to exposure such as health care workers. 286 Therefore, this limited sample supports the potential usefulness of serial rapid antigen testing in 287 detecting recent infections to implement containment measures and merits further study (38). 288 Importantly, the public health benefits of serial testing with RDTs should be studied further.

289 There are several advantages to rapid testing. CareStart has a lower turnaround time than 290 RT-gPCR, including 10 minutes to run the test on site where most of the test results were visible 291 in 3-4 minutes. Infected individuals can be notified of their status and begin isolation immediately, 292 resulting in less transmission to contacts compared to tests with longer turnaround times. In 293 addition, using anterior nasal swabs instead of the internationally accepted gold standard 294 nasopharyngeal swabs increases the acceptability of testing. However, it may also compromise 295 the sensitivity of antigen detecting RDTs, although a recent evaluation of swab types disputes 296 this possibility (39). The test is simple, and requires little training to be performed, making it more 297 amenable to self-administration and home testing. The price of RDTs is gradually decreasing to 298 become more affordable. Some individuals might test by RDT who would otherwise not be tested 299 at all. Therefore, a formal assessment of the public health impacts of RDTs should be conducted 300 in future studies.

301 A few factors may have compromised the performance characteristics of CareStart in this 302 study. We had limited control over or ability to monitor the order by which the two bilateral nasal 303 swabs were collected because of embedding the study in a 'real world' testing program. It is 304 possible that performing the PCR swab first may decrease the available viral load for the antigen 305 test. However, a recent evaluation of the Abbott BinaxNOW suggested that the order of swabs 306 had little impact on the test result (20). The tests were analyzed indoors to minimize temperature 307 fluctuations. However, the environmental temperature was not systematically monitored in this 308 semi-indoor setting (foyer of the War Memorial Building, Holyoke, MA). Since the study was 309 performed during the winter in Massachusetts, the tests were generally conducted at cold 310 temperatures, which could impact the RDT performance (15, 40). These results are, hence, 311 reflective of a real-world evaluation scenario, where lower temperatures and seasonal fluctuations 312 are expected in regions such as Massachusetts. Finally, study was conducted at the time when 313 vaccination against SARS-CoV-2 was low, which may affect the generalizability of these findings. 314 In conclusion, RDTs such as CareStart, can support SARS-CoV-2 testing efforts in 315 minimally or asymptomatic individuals. However, the impact of the limited sensitivity of these tests 316 on their positive predictive values reinforce caution. The moderate sensitivity of these tests means 317 that some potentially infectious individuals may be classified as SARS-CoV-2-negative. 318 Therefore, implementing RDTs for travel, home testing, or to guide re-openings of schools and 319 workplaces should be interpreted with caution and the utility of RDTs in each of these use cases 320 should be carefully evaluated. Furthermore, implementation studies to analyze their usefulness 321 and acceptability by both users and providers are necessary.

322

Demographics	Always Undetermined (N=3)	Always Negative (N=558)	Ever Positive (N=30)	Overall (N=591)
Age (Years)				
Mean (SD)	25.3 (3.51)	38.2 (17.9)	37.4 (15.4)	38.1 (17.8)
Median [Min, Max]	25 [22, 29]	36 [1, 85]	34.5 [16, 75]	36 [1, 85]
Sex				
Female	2 (66.7%)	294 (52.7%)	11 (36.7%)	307 (51.9%)
Male	1 (33.3%)	236 (42.3%)	14 (46.7%)	251 (42.5%)
Non-binary	0 (0%)	4 (0.7%)	0 (0%)	4 (0.7%)
Prefer not to answer	0 (0%)	24 (4.3%)	4 (13.3%)	28 (4.7%)
Not listed	0 (0%)	0 (0%)	1 (3.3%)	1 (0.2%)
Lives in Holyoke zip code				
Yes	3 (100%)	292 (52.3%)	13 (43.3%)	308 (52.1%)
No	0 (0%)	266 (47.7%)	17 (56.7%)	283 (47.9%)
Race/Ethnicity category				
Hispanic or LatinX	1 (33.3%)	248 (44.4%)	15 (50.0%)	264 (44.7%)
White Non-Hispanic	2 (66.7%)	262 (47%)	14 (46.7%)	278 (47.0%)
Asian Non-Hispanic	0 (0%)	5 (0.9%)	0 (0%)	5 (0.8%)
Black or African American Non-	0 (0%)	15 (2.7%)	0 (0%)	15 (2.5%)
Hispanic				
Native Hawaiian or Other Pacific	0 (0%)	1 (0.2%)	0 (0%)	1 (0.2%)
Islander Non-Hispanic				
Other Non-Hispanic	0 (0%)	8 (1.4%)	0 (0%)	8 (1.4%)
Two or more races Non-Hispanic	0 (0%)	4 (0.7%)	0 (0%)	4 (0.7%)
Prefer not to answer	0 (0%)	15 (2.7%)	1 (3.3%)	16 (2.7%)
Repeat tester				
No	3 (100%)	506 (90.7%)	22 (73.3%)	531 (89.8%)
Yes	0 (0%)	52 (9.3%)	8 (26.7%)	60 (10.2%)

324

325 Table 1A: Demographics of unique study participants who enrolled in the CareStart Rapid

326 Antigen Test evaluation at the Stop the Spread COVID-19 testing site in Holyoke, Massachusetts.

327

	Negative (N=631)	Positive (N=31)	Undetermined (N=4)	Overall (N=666)
Any symptoms				
No	554 (87.8%)	18 (58.1%)	1 (25.0%)	573 (86%)
Yes	77 (12.2%)	13 (41.9%)	3 (75.0%)	93 (14%)
Exposure				
Confirmed or suspected	196 (31.1%)	17 (54.8%)	4 (100%)	217 (32.6%)
No exposure	433 (68.6%)	14 (45.2%)	0 (0%)	447 (67.1%)
Did not answer	2 (0.3%)	0 (0%)	0 (0%)	2 (0.3%)
Prior COVID-19 test				
No	110 (17.4%)	9 (29.0%)	2 (50.0%)	121 (18.2%)
Yes	519 (82.3%)	22 (71.0%)	2 (50.0%)	543 (81.5%)
Missing	2 (0.3%)	0 (0%)	0 (0%)	2 (0.3%)

Table 1B: Tester symptoms, exposure history and prior COVID-19 testing per each CareStart

testing occurrence, including repeated tests from the same participants.

Result of N gene RT-qPCR	Negative (N=583)	Positive (N=52)	Undetermined (N=31)	Overall (N=666)
CareStart test result				
Negative	577 (99%)	26 (50%)	28 (90.3%)	631 (94.7%)
Positive	3 (0.5%)	25 (48.1%)	3 (9.7%)	31 (4.7%)
Undetermined	3 (0.5%)	1 (1.9%)	0 (0%)	4 (0.6%)

Table 2: Concordance between CareStart Test Results and RT-qPCR test results

	n	Total tests	Performance Characteristic	Estimate (%)	95% Confidence Interval
Rapid Test Results					
Positive	25	51	Sensitivity	49.0%	(34.8% - 63.4%)
Negative	577	580	Specificity	99.5%	(98.5% - 99.9%)

- 337 Table 3: Performance characteristics of CareStart test results benchmarked against the RT-
- 338 qPCR gold standard (excluding undetermined results).

Figure Legends:

- 340 **Figure 1:** Number of CareStart rapid antigen test administered by date (n=666). The bar colors
- 341 reflect the results of the rapid tests on different days.
- 342 **Figure 2:** Examples of images of CareStart rapid test showing variable band intensities.
- 343 **Figure 3:** N2 gene RT-qPCR Cycle threshold (Ct) values corresponding to positive and negative
- 344 CareStart rapid antigen test results for all RT-qPCR positive samples (n=52).
- 345 **Figure 4:** Calculated positive (left) and negative predictive values (right) based on the CareStart
- 346 performance characteristics and different prevalence estimates of SARS-CoV-2 infections.
- 347 **Figure 5:** Individuals who enrolled in the study multiple times and had at least one positive gold
- 348 standard RT-qPCR reference (n=11). The point colors reflect the different combinations of RT-
- 349 qPCR and CareStart rapid test results. The numbers above the point correspond to Ct values of
- 350 the RT-qPCR.
- 351

353 Acknowledgements

The Holyoke Board of Health was instrumental in coordinating study logistics with Fallon Ambulance Services who performed the swabs for RT-qPCR. The MA Department of Public Health and Ginko Bioworks donated the Access Bio testing kits and anterior nares SteriPack swabs for this study. The study was supported by an award from the Massachusetts Life Sciences Center Accelerating Coronavirus Testing Solutions (A.C.T.S) and the Sullivan Family Foundation (LCI).

362 **Potential conflicts of interest**

- 363 None.
- 364
- 365

366 **References**

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID in real time. Lancet Infect Dis. 2020;20(5):533-4. Epub 2020/02/23. doi:
 10.1016/S1473-3099(20)30120-1. PubMed PMID: 32087114; PMCID: PMC7159018.

370 Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, 2. 371 Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary 372 hospitals in Hubei Province. Chin Med J (Engl). 2020;133(9):1025-31. Epub 2020/02/12. 373 10.1097/CM9.00000000000744. PubMed PMID: doi: 32044814; PMCID: 374 PMC7147277.

- 375 3. Ramdas K, Darzi A, Jain S. 'Test, re-test, re-test': using inaccurate tests to greatly
 increase the accuracy of COVID-19 testing. Nat Med. 2020;26(6):810-1. Epub
 2020/05/14. doi: 10.1038/s41591-020-0891-7. PubMed PMID: 32398878; PMCID:
 378 PMC7215136.
- Hellou MM, Gorska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, Poran
 I, Leeflang M, Tacconelli E, Paul M. Nucleic-acid-amplification tests from respiratory
 samples for the diagnosis of coronavirus infections: systematic review and meta-analysis.
 Clin Microbiol Infect. 2020. Epub 2020/11/15. doi: 10.1016/j.cmi.2020.11.002. PubMed
 PMID: 33188933; PMCID: PMC7657614.
- 5. Brown RCH, Kelly D, Wilkinson D, Savulescu J. The scientific and ethical feasibility of immunity passports. Lancet Infect Dis. 2020. Epub 2020/10/20. doi: 10.1016/S1473-3099(20)30766-0. PubMed PMID: 33075284; PMCID: PMC7567527.
- 387 6. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A
 388 Narrative Review. Ann Intern Med. 2020;173(5):362-7. Epub 2020/06/04. doi:
 389 10.7326/M20-3012. PubMed PMID: 32491919; PMCID: PMC7281624.
- Quilty BJ, Clifford S, Hellewell J, Russell TW, Kucharski AJ, Flasche S, Edmunds
 WJ, Centre for the Mathematical Modelling of Infectious Diseases C-wg. Quarantine and
 testing strategies in contact tracing for SARS-CoV-2: a modelling study. Lancet Public
 Health. 2021;6(3):e175-e83. Epub 2021/01/24. doi: 10.1016/S2468-2667(20)30308-X.
 PubMed PMID: 33484644; PMCID: PMC7826085.
- 395 Pray IW, Ford L, Cole D, Lee C, Bigouette JP, Abedi GR, Bushman D, Delahoy 8. 396 MJ, Currie D, Cherney B, Kirby M, Fajardo G, Caudill M, Langolf K, Kahrs J, Kelly P, Pitts 397 C, Lim A, Aulik N, Tamin A, Harcourt JL, Queen K, Zhang J, Whitaker B, Browne H, Medrzycki M, Shewmaker P, Folster J, Bankamp B, Bowen MD, Thornburg NJ, Goffard 398 399 K, Limbago B, Bateman A, Tate JE, Gieryn D, Kirking HL, Westergaard R, Killerby M, 400 Group CC-SL. Performance of an Antigen-Based Test for Asymptomatic and 401 Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, 402 September-October 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1642-7. Epub 403 2021/01/01. doi: 10.15585/mmwr.mm695152a3. PubMed PMID: 33382679.
- 404 9. Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle405 Income Countries. JAMA. 2020;323(16):1549-50. Epub 2020/03/17. doi:
 406 10.1001/jama.2020.4169. PubMed PMID: 32176764.
- 407 10. WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid
 408 immunoassays. Interim Guidance. 2020;11 September 2020(Accessed online:

409 <u>https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-</u>
 410 <u>2infection-using-rapid-immunoassays</u>).

11. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, Dittrich S, 411 412 Emperador D, Takwoingi Y, Cunningham J, Beese S, Domen J, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S, Hooft L, Leeflang MM, McInnes MD, 413 414 Spijker R, Van den Bruel A, Cochrane C-DTAG. Rapid, point-of-care antigen and 415 molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst 416 Rev. 2021;3:CD013705. Epub 2021/03/25. doi: 10.1002/14651858.CD013705.pub2. 417 PubMed PMID: 33760236. FDA. In Vitro Diagnostics EUAs. . U S Food and Drug Administration. 418 12. 419 2021;Published online March 8, 2021.(Accessed March 2021. 9. 420 https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergencyuse-authorizations-medical-devices/vitro-diagnostics-euas). 421 422 13. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A, 423 Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J, 424 Ackerman R, Cooper CK. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test 425 performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-426 of-care test. J Clin Microbiol. 2020. Epub 2020/10/08. doi: 10.1128/JCM.02338-20. 427 PubMed PMID: 33023911. 428 Landaas ET, Storm ML, Tollanes MC, Barlinn R, Kran AB, Bragstad K, Christensen 14. 429 A, Andreassen T. Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, 2021;137:104789. 430 J Clin Norwegian cohort. Virol. Epub 2021/03/20. doi: 431 10.1016/j.jcv.2021.104789. PubMed PMID: 33736946; PMCID: PMC7944803. 432 Pollock NR, Jacobs JR, Tran K, Cranston AE, Smith S, O'Kane CY, Roady TJ, 15. 433 Moran A, Scarry A, Carroll M, Volinsky L, Perez G, Patel P, Gabriel S, Lennon NJ, Madoff 434 LC, Brown C, Smole SC. Performance and Implementation Evaluation of the Abbott 435 BinaxNOW Rapid Antigen Test in a High-throughput Drive-through Community Testing 436 Site in Massachusetts. J Clin Microbiol. 2021. Epub 2021/02/25. doi: 10.1128/JCM.00083-21. PubMed PMID: 33622768. 437 Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marguez C, Rubio L, Chamie 438 16. 439 G, Martinez J, Peng J, Black D, Wu W, Pak J, Laurie MT, Jones D, Miller S, Jacobo J, 440 Rojas S, Rojas S, Nakamura R, Tulier-Laiwa V, Petersen M, Havlir DV, Consortium C, 441 DeRisi J. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at 442 a public plaza testing site in San Francisco. J Infect Dis. 2021. Epub 2021/01/05. doi: 443 10.1093/infdis/jiaa802. PubMed PMID: 33394052; PMCID: PMC7799021. 444 Pollock NR. Tran K. Jacobs JR. Cranston AE. Smith S. O'Kane CY. Roady TJ. 17. 445 Moran M, Scarry A, Carroll M, Volinsky L, Perez G, Patel P, Gabriel S, Lennon NJ, Madoff LC, Brown C, Smole SC. Performance and Operational Evaluation of the Access Bio 446 447 CareStart Rapid Antigen Test in a High-throughput Drive-through Community Testing Site 448 in Massachusetts. MedRxiv. 2021:Pre-print: 449 https://www.medrxiv.org/content/10.1101/2021.03.07.21253101v1.full-text. (Accessed 450 online: April 5, 2021).

451 18. Smith RL, Gibson LL, Martinez PP, Ke R, Mirza A, Conte M, Gallagher N, Conte 452 A, Wang L, Fredrickson R, Edmonson DC, Baughman ME, Chiu KK, Choi H, Jensen TW, 453 Scardina KR, Bradley S, Gloss SL, Reinhart C, Yedetore J, Owens AN, Broach J, Barton B. Lazar P. Henness D. Young T. Dunnett A. Robinson ML. Mostafa HH. Pekosz A. 454 Manabe YC, Heetderks WJ, McManus DD, Brooke CB. Longitudinal assessment of 455 456 diagnostic test performance over the course of acute SARS-CoV-2 infection. medRxiv. 457 2021. Epub 2021/04/02. doi: 10.1101/2021.03.19.21253964. PubMed PMID: 33791719; 458 PMCID: PMC8010751. 459 Kilic A. Hiestand B. Palavecino E. Evaluation of Performance of the BD Veritor 19. 460 SARS-CoV-2 Chromatographic Immunoassay Test in COVID-19 Symptomatic Patients. 461 J Clin Microbiol. 2021. Epub 2021/02/28. doi: 10.1128/JCM.00260-21. PubMed PMID: 462 33637583. 463 Okove NC, Barker AP, Curtis K, Orlandi RR, Snavely EA, Wright C, Hanson KE, 20. 464 Pearson LN. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for 465 Screening Asymptomatic Individuals in a University Setting. J Clin Microbiol. 2021. Epub 466 2021/01/30. doi: 10.1128/JCM.03282-20. PubMed PMID: 33509809. FDA. Coronavirus (COVID-19) Update: FDA Continues to Advance Over-the 467 21. Counter and Other Screening Test Development. U S Food and Drug Administration. 468 469 2021; Press Release, Published online: March 31, 2021. 470 Epidemiologists) CCoSaT. Update to the standardized surveillance case definition 22. 471 and national notification for 2019 novel coronavirus disease (COVID-19). infectious 472 Disease Committee. 2020;Accessed online: 473 https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/positionstatement2020/Interi 474 m-20-ID-02 COVID-19.pdf. 475 Clinical Research Sequencing Platform (CRSP) LatBIoMaH. CRSP SARS-CoV-2 23. 476 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay. 477 https://wwwfdagov/media/139858/download. 478 24. Diagnostics A. CareStart COVID-19 Antigen: Rapid Diagnostic Test for the 479 Detection of SARS-CoV-2 Antigen Accessed online: https://accessbiodiagnosticsnet/wp-480 content/uploads/2021/02/EUA-accessbio-CareStart-Antigen-ifupdf. 2020:Instructions for 481 Use Under Emergency Use Authorization. Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Hoang TV, Colson P, Raoult D, La Scola 482 25. B. Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives 483 484 Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome 485 Coronavirus 2 Isolates. Clinical Infectious Diseases. 2020;Correspondence. 486 26. Hernaez R, Thrift AP. High Negative Predictive Value, Low Prevalence, and 487 Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol. 488 2017;15(9):1355-8. Epub 2017/05/16. doi: 10.1016/j.cgh.2017.05.002. PubMed PMID: 28501535. 489 490 27. Sval K. Guidelines on newly identified limitations of diagnostic tools for COVID-19 491 and consequences. J Med Virol. 2021;93(4):1837-42. Epub 2020/11/18. doi: 10.1002/jmv.26673. PubMed PMID: 33200414; PMCID: PMC7753543. 492 493 Dryden-Peterson S, Velasquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO. 28. 494 Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic. 495 JAMA Netw Open. 2021;4(2):e2037067. 2021/02/10. Epub doi:

496 10.1001/jamanetworkopen.2020.37067. PubMed PMID: 33560423; PMCID:
 497 PMC7873783.

498 29. Figueroa JF, Wadhera RK, Lee D, Yeh RW, Sommers BD. Community-Level
499 Factors Associated With Racial And Ethnic Disparities In COVID-19 Rates In
500 Massachusetts. Health Aff (Millwood). 2020;39(11):1984-92. Epub 2020/08/28. doi:
501 10.1377/hlthaff.2020.01040. PubMed PMID: 32853056.

30. Weiss A, Jellingso M, Sommer MOA. Spatial and temporal dynamics of SARSCoV-2 in COVID-19 patients: A systematic review and meta-analysis. EBioMedicine.
2020;58:102916. Epub 2020/07/28. doi: 10.1016/j.ebiom.2020.102916. PubMed PMID:
32711256; PMCID: PMC7374142.

- van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba 506 31. N, van den Akker JPC, Endeman H, Gommers D, Cornelissen JJ, Hoek RAS, van der 507 Eerden MM, Hesselink DA, Metselaar HJ, Verbon A, de Steenwinkel JEM, Aron GI, van 508 509 Gorp ECM, van Boheemen S, Voermans JC, Boucher CAB, Molenkamp R, Koopmans 510 MPG, Geurtsvankessel C, van der Eijk AA. Duration and key determinants of infectious 511 virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat 512 Commun. 2021;12(1):267. Epub 2021/01/13. doi: 10.1038/s41467-020-20568-4. 513 PubMed PMID: 33431879; PMCID: PMC7801729.
- 32. Perez-Garcia F, Romanyk J, Gomez-Herruz P, Arroyo T, Perez-Tanoira R, Linares
 M, Perez Ranz I, Labrador Ballestero A, Moya Gutierrez H, Ruiz-Alvarez MJ, CuadrosGonzalez J. Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests
 to diagnose SARS-CoV-2 infection. J Clin Virol. 2021;137:104781. Epub 2021/02/28. doi:
 10.1016/j.jcv.2021.104781. PubMed PMID: 33639492; PMCID: PMC7897407.
- 33. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello
 A, Hedley A, Schiffman Z, Doan K, Bastien N, Li Y, Van Caeseele PG, Poliquin G.
 Predicting infectious SARS-CoV-2 from diagnostic samples. Clinical infectious diseases
 an official publication of the Infectious Diseases Society of America. 2020. Epub
 2020/05/23. doi: 10.1093/cid/ciaa638. PubMed PMID: 32442256; PMCID: PMC7314198.
- 524 34. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, 525 Nadler V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R. Initial report of 526 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 527 2021. Epub 2021/03/31. doi: 10.1038/s41591-021-01316-7. PubMed PMID: 33782619.
- 35. Teran RA, Walblay KA, Shane EL, Xydis S, Gretsch S, Gagner A, Samala U, Choi
 H, Zelinski C, Black SR. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing
 Facility Residents and Staff Members Chicago, Illinois, December 2020-March 2021.
 MMWR Morb Mortal Wkly Rep. 2021;70(17):632-8. Epub 2021/04/30. doi:
 10.15585/mmwr.mm7017e1. PubMed PMID: 33914721; PMCID: PMC8084122 Journal
 Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest
 were disclosed.
- 36. Peng J, Liu J, Mann SA, Mitchell AM, Laurie MT, Sunshine S, Pilarowski G, Ayscue
 P, Kistler A, Vanaerschot M, Li LM, McGeever A, Chow ED, Marquez C, Nakamura R,
 Rubio L, Chamie G, Jones D, Jacobo J, Rojas S, Rojas S, Tulier-Laiwa V, Black D,
 Martinez J, Naso J, Schwab J, Petersen M, Havlir D, DeRisi J, Team ID. Estimation of
 secondary household attack rates for emergent spike L452R SARS-CoV-2 variants

540 detected by genomic surveillance at a community-based testing site in San Francisco. 541 Clinical infectious diseases : an official publication of the Infectious Diseases Society of

542 America. 2021. Epub 2021/04/01. doi: 10.1093/cid/ciab283. PubMed PMID: 33788923.

543 37. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Gary DS, Roger-


- 544 Dalbert C, Leitch J, Cooper CK. Antigen-Based Testing but Not Real-Time Polymerase
- 545 Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral 546 Culture. Clinical infectious diseases : an official publication of the Infectious Diseases
- 546 Culture. Clinical infectious diseases : an official publication of the Infectious Diseases 547 Society of America. 2021. Epub 2021/01/23. doi: 10.1093/cid/ciaa1706. PubMed PMID:
- 548 33479756; PMCID: PMC7929138.
- 549 38. Mina MJ, Peto TE, Garcia-Finana M, Semple MG, Buchan IE. Clarifying the
- evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19.
 Lancet. 2021. Epub 2021/02/21. doi: 10.1016/S0140-6736(21)00425-6. PubMed PMID:
- **33609444**.
- 553 39. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. 554 Exploring alternative swabs for use in SARS-CoV-2 detection from the oropharynx and 555 anterior nares. J Virol Methods. 2020;285:113948. Epub 2020/08/14. doi: 556 10.1016/j.jviromet.2020.113948. PubMed PMID: 32783913; PMCID: PMC7415171.

40. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kuhne A, Fischer C, Sacks

558 JA, Corman VM, Muller MA, Drosten C, Drexler JF. Impaired performance of SARS-CoV-

- 559 2 antigen-detecting rapid diagnostic tests at elevated and low temperatures. J Clin Virol.
- 560 2021;138:104796. Epub 2021/03/28. doi: 10.1016/j.jcv.2021.104796. PubMed PMID: 561 33773413; PMCID: PMC7962993.









Negative

Positive (weak)





Positive (medium)




Positive (strong)











Supplementary Table 1: Study participants who enrolled multiple times for testing with both RT-qPCR and Access Bio CareStart

Total Repeat Testers	60	Number of tests after first test
Tested 2 Times	50	50
Tested 3 Times	6	12
Tested 4 Times	3	9
Tested 5 Times	1	4
Total repeat tests		75

Demographics	Always Negative (N=266)	Ever Positive (N=17)	Overall (N=283)
Age (Years) Mean (SD) Median [Min, Max] Sex	39.3 (18.5%) 37 [4 - 82]	36.2 (13.3%) 31 [23 - 66]	39.1 (18.2%) 36 [4 - 82]
Female Male Non-binary Prefer not to answer	145 (54.5%) 108 (40.6%) 2 (0.8%) 11(4.1%)	6 (35.3%) 7 (41.2%) 0 (0%) 4 (23.5%)	151 (53.4%) 115 (40.6%) 2 (0.7%) 15 (5.3%)
Race/Ethnicity category Hispanic or LatinX Black or African American Non-Hispanic Two or more races Non-Hispanic White Non-Hispanic Prefer not to answer	157 (59%) 5 (1.9%) 3 (1.1%) 95 (35.7%) 6 (2.3%)	9 (52.9%) 0 (0%) 0 (0%) 7 (41.2%) 1 (5.9%)	166 (58.7%) 5 (1.8%) 3 (1.1%) 102 (36%) 7 (2.5%)
Repeat tester No Yes	229 (86.1%) 37 (13.9%)	13 (76.5%) 4 (23.5%)	242 (85.5%) 41 (14.5%)

Supplementary Table 2: Demographics of study participants who are residents of Holyoke, Massachusetts (N=283)

Supplementary Table 3: Symptoms reported at all visits

	Inconclusive (N=4)	Negative (N=631)	Positive (N=31)	Overall (N=666)
Cough No Yes	2 (50.0%) 2 (50.0%)	600 (95.1%) 31 (4.9%)	24 (77.4%) 7 (22.6%)	626 (94.0%) 40 (6.0%)
Sore Throat No Yes	1 (25.0%) 3 (75.0%)	608 (96.4%) 23 (3.6%)	28 (90.3%) 3 (9.7%)	637 (95.6%) 29 (4.4%)
Chills No Yes	3 (75.0%) 1 (25.0%)	623 (98.7%) 8 (1.3%)	30 (96.8%) 1 (3.2%)	656 (98.5%) 10 (1.5%)
Shortness of Breath No Yes	3 (75.0%) 1 (25.0%)	620 (98.3%) 11 (1.7%)	31 (100%) 0 (0%)	654 (98.2%) 12 (1.8%)
Fever No Yes	3 (75.0%) 1 (25.0%)	623 (98.7%) 8 (1.3%)	28 (90.3%) 3 (9.7%)	654 (98.2%) 12 (1.8%)
Muscle Aches or Soreness No Yes	2 (50.0%) 2 (50.0%)	611 (96.8%) 20 (3.2%)	23 (74.2%) 8 (25.8%)	636 (95.5%) 30 (4.5%)
Nausea, Vomiting or Diarrhea No Yes	2 (50.0%) 2 (50.0%)	612 (97.0%) 19 (3.0%)	30 (96.8%) 1 (3.2%)	644 (96.7%) 22 (3.3%)
Decreased Sense of Smell or Taste No Yes	3 (75.0%) 1 (25.0%)	617 (97.8%) 14 (2.2%)	27 (87.1%) 4 (12.9%)	647 (97.1%) 19 (2.9%)
Loss of Appetite No Yes	4 (100%) 0 (0%)	623 (98.7%) 8 (1.3%)	29 (93.5%) 2 (6.5%)	656 (98.5%) 10 (1.5%)
General Weakness or Fatigue No Yes	3 (75.0%) 1 (25.0%)	604 (95.7%) 27 (4.3%)	27 (87.1%) 4 (12.9%)	634 (95.2%) 32 (4.8%)
Headache No Yes	2 (50.0%) 2 (50.0%)	587 (93.0%) 44 (7.0%)	24 (77.4%) 7 (22.6%)	613 (92.0%)

	RT-qPCR Results						
CareStart Results	Negative (N=61)	Positive (N=29)	Undetermined (N=3)	Overall (N=93)			
Negative	59 (96.7%)	15 (51.7%)	3 (100%)	77 (82.8%)			
Positive	2 (3.3%)	1 (3.4%)	0 (0%)	3 (3.2%)			
Undetermined	0 (0%)	13 (44.8%)	0 (0%)	13 (14%)			

Supplementary Table 4A: CareStart test results compared to RT-qPCR in symptomatic individuals only

Supplementary Table 4B: CareStart test result sensitivity and specificity in symptomatic individuals only

	RT-qPCR Results						
Туре	n N Estimate 95%						
Sensitivity	13	28	46.4%	27.5% - 66.1%			
Specificity	59	59	100%	95% - 100%			

Supplementary Table 4C: CareStart test results compared to RT-qPCR in asymptomatic individuals only

	RT-qPCR Results						
CareStart Results	Negative (N=522)	Positive (N=23)	Undetermined (N=28)	Overall (N=573)			
Negative	518 (99.2%)	11 (47.8%)	25 (89.3%)	554 (96.7%)			
Positive	3 (0.6%)	12 (52.2%)	3 (10.7%)	18 (3.1%)			
Undetermined	1 (0.2%)	0 (0%)	0 (0%)	1 (0.2%)			

Supplementary Table 4D: CareStart test result sensitivity and specificity in asymptomatic individuals only

	RT-qPCR Results				
Туре	n	Ν	Estimate	95% CI	
Sensitivity	12	23	52.2%	30.6% - 73.2%	
Specificity	518	521	99.4%	98.3% - 99.9%	

Supplementary Table 5A: CareStart test results compared to RT-qPCR using Ct positivity threshold of < 30.

ntary Table 5A: CareStart test results compared to RT-qPCR using Ct positivity threshold of							
Negative (Ct>=30) N=597	Positive (Ct <i><</i> 30) N=38	Undetermined N=31	Overall N=666				
590 (98.8%)	13 (34.2%)	28 (90.3%)	631 (94.7%)				
4 (0.7%)	24 (63.2%)	3 (9.7%)	31 (4.7%)				
3 (0.5%)	1 (2.6%)	0 (0%)	4 (0.6%)				
-	Negative (Ct >=30) N=597 590 (98.8%) 4 (0.7%)	Negative (Ct >=30) Positive (Ct <30) N=597 N=38 590 (98.8%) 13 (34.2%) 4 (0.7%) 24 (63.2%)	Negative (Ct >=30) Positive (Ct <30) Undetermined N=597 N=38 N=31 590 (98.8%) 13 (34.2%) 28 (90.3%) 4 (0.7%) 24 (63.2%) 3 (9.7%)				

Supplementary Table 5B: CareStart test result sensitivity and specificity using Ct positivity threshold of < 30.

Туре	n	Ν	Estimate	95% CI
Sensitivity	24	37	64.9%	47.5%-79.8%
Specificity	590	594	99.3%	98.3% - 99.8%